Stay updated with breaking news from Ashley Buford. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-PD-1 alone in similar... | May 25, 2023
FinancialContent fully hosted finance channel
With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for postmenopausal
Investegate announcements from NOVARTIS AG CHF0.50(REGD), New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i